O' (happy) Day?

Only yesterday:

"While the “vast majority of deals will still be earlier stage by definition,” investors should “rest assured” that Gilead is working to supplement its late-stage portfolio through M&A, too. As it does, it’ll be looking for targets that fit into its core areas of viral diseases, inflammatory diseases, fibrotic diseases and oncology, with a particular focus on immuno-modulatory drugs. "

https://www.fiercepharma.com/pharma/want-clue...pagos-deal